This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cancer Neoantigen Vaccines
February 2, 2023 | 1-Day Digital Conference
Digital Conference8:00AM EST // 1:00PM GMT // 2:00PM CET
Menu

Karin Jooss
EVP & Head of R&D at Gritstone Bio
Speaker

Agenda Sessions

  • Neoantigen Immunotherapy For Solid Tumors – Molecular Responses and Clinical Benefit In End-Stage Patients – Moving Upstream

    , 10:50
    View Session

At this event

Prev
Next
Jeff Bockman
Executive Vice President, Commercial BioConsulting and Head of Oncology
Lumanity

See Karin at Cancer Neoantigen Vaccines